Saturday, 31 October 2026European Markets

DEKUPLE And KINEPOLIS GROUP Have A High Dividend Yield And Return On Equity In The Communication Services Sector.

Loading stream...

(vianews) - dekuple (dkupl.pa) is among this list of stock assets with the highest dividend rate and return on equity on the communication services sector.

financial asset price forward dividend yield return on equity
dekuple (dkupl.pa) €30.20 2.87% 29.55%
kinepolis group (kin.br) €40.15 1.38% 20.21%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. dekuple (dkupl.pa)

2.87% forward dividend yield and 29.55% return on equity

adlpartner sa provides marketing solutions in france and internationally. the company designs, markets, and implements customer loyalty and relationship management services; markets and sells magazine press subscriptions; and offers marketing solutions and insurance brokerage services. it also provides consulting and technology, marketing engineering agency, and creator of customer relation services. the company was founded in 1972 and is based in montreuil, france. adlpartner sa is a subsidiary of sogespa sas.

earnings per share

as for profitability, dekuple has a trailing twelve months eps of €2.25.

pe ratio

dekuple has a trailing twelve months price to earnings ratio of 13.42. meaning, the purchaser of the share is investing €13.42 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.55%.

yearly top and bottom value

dekuple's stock is valued at €30.20 at 07:30 est, way below its 52-week high of €42.50 and way higher than its 52-week low of €21.70.

revenue growth

year-on-year quarterly revenue growth grew by 8.8%, now sitting on 208.1m for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, dekuple's stock is considered to be overbought (>=80).

volume

today's last reported volume for dekuple is 196 which is 68.69% below its average volume of 626.

more news about dekuple.

2. kinepolis group (kin.br)

1.38% forward dividend yield and 20.21% return on equity

kinepolis group nv operates cinema complexes in belgium, the netherlands, france, spain, luxembourg, switzerland, poland, canada, and the united states. the company operates cinema complexes under the kinepolis, landmark cinemas, and mjr theatres brands. it also organizes company events; sells vouchers to companies and publicity campaigns in the cinema; and beverages and snacks in the cinema complexes, as well as operates the self-service shop and other in-theatre sales concepts. it is also involved in distribution of movies, as well as alternative content, such as concerts, kids content, etc.; production and promotion of flemish films; screen advertising; and rental of real estate. kinepolis group nv was incorporated in 1976 and is based in brussels, belgium.

earnings per share

as for profitability, kinepolis group has a trailing twelve months eps of €2.03.

pe ratio

kinepolis group has a trailing twelve months price to earnings ratio of 19.78. meaning, the purchaser of the share is investing €19.78 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.21%.

volume

today's last reported volume for kinepolis group is 3638 which is 80.38% below its average volume of 18550.

revenue growth

year-on-year quarterly revenue growth declined by 14.9%, now sitting on 563m for the twelve trailing months.

more news about kinepolis group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com